Option Care Health (OPCH) Q3 2025 earnings summary

Executive summary

• Net revenue for Q3 2025 reached $1.44 billion, up 12.2% year-over-year, driven by balanced growth in acute (mid-teens) and chronic (low double-digit) therapies, despite headwinds from Stelara biosimilar adoption.

• Net income for Q3 2025 was $51.8 million, a 3.8% decrease from Q3 2024, with a net margin of 3.6%.

• Gross profit rose 6.3% to $272.9 million, with gross margin declining to 19.0% due to higher-cost therapies and reduced procurement spread.

• Leadership transition included new CFO Meenal Sethna and VP of Investor Relations Stephen Shulstein.

• CEO highlighted balanced growth and strong execution amid a dynamic regulatory and competitive environment.

Financial highlights

• Net revenue for Q3 2025: $1.44 billion, up 12.2% year-over-year; nine-month net revenue: $4.18 billion, up 14.6%.

• Gross profit for Q3 2025: $272.9 million (up 6.3%); nine-month gross profit: $805.0 million.

• Adjusted EBITDA for Q3 2025: $119.5 million (up 3.4%), margin 8.3%.

• Adjusted EPS for Q3 2025: $0.45 (up 9.8%); GAAP diluted EPS: $0.32 (up 3.2%).

• Year-to-date cash flow from operations: $222.6 million.

Outlook and guidance

• Raised full-year 2025 guidance: net revenue $5.6–$5.65 billion, adjusted EBITDA $468–$473 million, adjusted EPS $1.68–$1.72.

• Cash flow from operations expected to exceed $320 million for the year.

• Guidance incorporates expectations for tariffs and policy changes, with no material impact anticipated in 2025.

• Management expects continued pressure on gross margin due to therapy mix and procurement spread.

• Effective tax rate expected at 25% to 27%; net interest expense $55–$57 million.